Cargando…

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus

INTRODUCTION: The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS: Pooled data from 20 trials were analyzed for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinduryte Schorling, Ona, Clark, Douglas, Zwiener, Isabella, Kaspers, Stefan, Lee, Jisoo, Iliev, Hristo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370973/ https://www.ncbi.nlm.nih.gov/pubmed/32372290 http://dx.doi.org/10.1007/s12325-020-01329-7

Ejemplares similares

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
por: Kohler, Sven, et al.
Publicado: (2017)

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
por: Yabe, Daisuke, et al.
Publicado: (2018)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
por: Ceriello, Antonio, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus
por: Kanada, Shigeto, et al.
Publicado: (2013)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
por: Baron, Kyle T., et al.
Publicado: (2016)

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials
por: Zhang, Yun-Jing, et al.
Publicado: (2018)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
por: Sone, Hirohito, et al.
Publicado: (2019)

Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
por: Chauhan, Sukhjinder, et al.
Publicado: (2023)

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
por: Yasui, Atsutaka, et al.
Publicado: (2018)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
por: Levine, Matthew J.
Publicado: (2017)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
por: Moon, Jun Sung, et al.
Publicado: (2023)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study
por: Samkari, Mayada M., et al.
Publicado: (2023)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
por: Pathan, M D Faruque, et al.
Publicado: (2022)

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
por: Schwaiger, Elisabeth, et al.
Publicado: (2019)

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
por: Neeland, Ian J, et al.
Publicado: (2016)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018)

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l7pplbqojrmnvkhp516qi79nsq